AU2011329872B2 - Methods for producing recombinant proteins - Google Patents

Methods for producing recombinant proteins Download PDF

Info

Publication number
AU2011329872B2
AU2011329872B2 AU2011329872A AU2011329872A AU2011329872B2 AU 2011329872 B2 AU2011329872 B2 AU 2011329872B2 AU 2011329872 A AU2011329872 A AU 2011329872A AU 2011329872 A AU2011329872 A AU 2011329872A AU 2011329872 B2 AU2011329872 B2 AU 2011329872B2
Authority
AU
Australia
Prior art keywords
cell
polyclonal
cells
cell population
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011329872A
Other languages
English (en)
Other versions
AU2011329872A1 (en
Inventor
Vincent W. Coljee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excelimmune Inc
Original Assignee
Excelimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excelimmune Inc filed Critical Excelimmune Inc
Publication of AU2011329872A1 publication Critical patent/AU2011329872A1/en
Application granted granted Critical
Publication of AU2011329872B2 publication Critical patent/AU2011329872B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2011329872A 2010-11-16 2011-11-16 Methods for producing recombinant proteins Active AU2011329872B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41422510P 2010-11-16 2010-11-16
US61/414,225 2010-11-16
PCT/US2011/061092 WO2012068317A2 (en) 2010-11-16 2011-11-16 Methods for producing recombinant proteins

Publications (2)

Publication Number Publication Date
AU2011329872A1 AU2011329872A1 (en) 2013-06-06
AU2011329872B2 true AU2011329872B2 (en) 2017-04-13

Family

ID=45406837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011329872A Active AU2011329872B2 (en) 2010-11-16 2011-11-16 Methods for producing recombinant proteins

Country Status (7)

Country Link
US (2) US8617881B2 (enExample)
EP (1) EP2640743B1 (enExample)
JP (1) JP6092782B2 (enExample)
AU (1) AU2011329872B2 (enExample)
CA (1) CA2817751C (enExample)
DK (1) DK2640743T3 (enExample)
WO (1) WO2012068317A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7095994B2 (ja) 2015-03-02 2022-07-05 アドヴェラム バイオテクノロジーズ， インコーポレイテッド ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
TWI554608B (zh) * 2015-03-27 2016-10-21 Univ China Medical A nucleic acid sequence segment for enhancing protein expression, an expression vector comprising a sequence segment thereof, and a kit comprising its expression vector
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
EP3810649A1 (en) 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
AU2022291273A1 (en) * 2021-06-10 2024-01-25 Janssen Biotech, Inc. Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004061104A2 (en) * 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US20090111142A1 (en) * 2007-05-25 2009-04-30 Lars Soegaard Nielsen Method for manufacturing a recombinant polyclonal protein
WO2009129814A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5686120A (en) 1995-05-22 1997-11-11 Wisconsin Alumni Research Foundation Pre-mRNA processing enhancer and method for intron-independent gene expression
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
AU6364800A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Dna recombination in eukaryotic cells by the bacteriophage phic31 recombination system
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
CA2413156C (en) 2000-07-03 2009-08-18 Gala Design, Inc. Expression vectors
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
ES2785223T3 (es) * 2006-06-21 2020-10-06 Uniqure Ip Bv Células de insecto para la producción de vectores de AAV

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004061104A2 (en) * 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US20090111142A1 (en) * 2007-05-25 2009-04-30 Lars Soegaard Nielsen Method for manufacturing a recombinant polyclonal protein
WO2009129814A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Huang et al (2007) Journal of Immunological Methods, April, 322(1-2):28-39 *
Nielsen et al (2010) Molecular Biotechnology, July, 45(3):257-266 *

Also Published As

Publication number Publication date
US8617881B2 (en) 2013-12-31
CA2817751A1 (en) 2012-05-24
WO2012068317A3 (en) 2012-08-16
DK2640743T3 (en) 2017-01-23
JP2014501505A (ja) 2014-01-23
US20140127743A1 (en) 2014-05-08
AU2011329872A1 (en) 2013-06-06
US9447174B2 (en) 2016-09-20
EP2640743A2 (en) 2013-09-25
WO2012068317A2 (en) 2012-05-24
CA2817751C (en) 2019-04-30
US20120302464A1 (en) 2012-11-29
EP2640743B1 (en) 2016-10-05
JP6092782B2 (ja) 2017-03-08

Similar Documents

Publication Publication Date Title
CA2817751C (en) Methods for producing recombinant proteins
US20230340085A1 (en) Lentiviral vector expressing membrane-anchored or secreted antibody
Fuchs et al. Liver-directed but not muscle-directed AAV-antibody gene transfer limits humoral immune responses in rhesus monkeys
AU2025267421A1 (en) Anti-C1S antibodies and methods of use thereof
US20190240328A1 (en) Novel humanized anti-ebola antibodies useful in preventing ebola infections
US20230227858A1 (en) Cell lines with multiple docks for gene insertion
JP7848138B2 (ja) 改変型上皮成長因子受容体及び細胞追跡におけるその使用
WO2022188689A1 (zh) 使用双重病毒载体系统递送抗体
Schnepp et al. Vector-mediated antibody gene transfer for infectious diseases
CN117363656A (zh) 核酸构建体及其用途
US20250375536A1 (en) Vector
US20250242018A1 (en) Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
CN113039270A (zh) 用于蛋白质制造的载体
WO2025133635A1 (en) Therapies for preventing or treating inflammatory eye disease
US20260043046A1 (en) Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
US20250277048A1 (en) The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
Chiyyeadu et al. Therapeutic antibody delivery: vector tools to boost efficacy and affordability
HK40096820A (zh) 核酸构建体及其用途
HK40093222A (zh) 用於基因治疗的核酸构建体及其用途
HK40093222B (zh) 用於基因治疗的核酸构建体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)